← Back to All US Stocks

GoHealth, Inc. (GOCO) Stock Fundamental Analysis & AI Rating 2026

GOCO Nasdaq Insurance Agents, Brokers & Service DE CIK: 0001808220
Recently Updated • Analysis: May 19, 2026 • SEC Data: 2026-03-31
📅 Next earnings: May 26, 2026 (tomorrow) • TBD ET • All earnings →
Combined AI Rating
STRONG SELL
88% Confidence
STRONG AGREEMENT
STRONG SELL
95% Conf
STRONG SELL
82% Conf

📊 GOCO Key Takeaways

Revenue: $11.9M
Net Margin: -312.0%
Free Cash Flow: $7.0M
Current Ratio: 2.03x
Debt/Equity: 306.49x
EPS: $-2.36
AI Rating: STRONG SELL with 95% confidence
GoHealth, Inc. (GOCO) receives a STRONG SELL rating with 88% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $11.9M, net profit margin of -312.0%, and return on equity (ROE) of -1,744.3%, GoHealth, Inc. demonstrates mixed fundamentals in the Finance sector. Below is our complete GOCO stock analysis for 2026.

Is GoHealth, Inc. (GOCO) a Good Investment?

Claude

GoHealth is in severe financial distress with a 54.7% YoY revenue collapse, operating losses of -$34.8M, and catastrophic leverage (306.49x debt-to-equity). The company cannot service its $653.1M debt burden with only $2.1M in equity and negative interest coverage of -1.9x, indicating imminent solvency risk.

ChatGPT

Fundamentals are severely impaired: revenue has halved, margins are deeply negative, and free cash flow remains sharply negative. Leverage is extreme with thin equity and negative interest coverage, elevating solvency risk despite acceptable near‑term liquidity. A credible turnaround would require material cost resets and sustained revenue stabilization not evidenced in current results.

Why Buy GoHealth, Inc. Stock? GOCO Key Strengths

Claude
  • + Positive operating cash flow of $7.0M demonstrates some business cash generation
  • + Acceptable short-term liquidity with 2.03x current ratio
  • + $917.9M in total assets provide potential liquidation value
ChatGPT
  • + Solid near-term liquidity (current and quick 2.02x)
  • + Meaningful revenue base (~$362M) if stabilized
  • + Capital-light profile (low capex) with slight YoY net loss improvement

GOCO Stock Risks: GoHealth, Inc. Investment Risks

Claude
  • ! Debt-to-equity ratio of 306.49x indicates technical insolvency and bankruptcy risk
  • ! 54.7% YoY revenue decline signals fundamental business model failure
  • ! Negative interest coverage (-1.9x) means company cannot service $653.1M debt from operations, requiring restructuring or asset sales
ChatGPT
  • ! Extreme leverage (16.8x D/E) and negative interest coverage (-23x) indicate solvency risk
  • ! Severe revenue contraction (-54.7% YoY) with deeply negative margins
  • ! Persistent cash burn (OCF -$121.9M; FCF -$130.2M) and very thin equity ($37.9M)

Key Metrics to Watch

Claude
  • * Revenue stabilization and return to growth
  • * Operating cash flow sustainability amid losses
  • * Debt restructuring or covenant violation developments
ChatGPT
  • * Operating cash flow
  • * Interest coverage

GoHealth, Inc. (GOCO) Financial Metrics & Key Ratios

Revenue
$11.9M
Net Income
$-37.2M
EPS (Diluted)
$-2.36
Free Cash Flow
$7.0M
Total Assets
$917.9M
Cash Position
$39.9M

💡 AI Analyst Insight

The 58.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.03x current ratio provides a solid financial cushion.

GOCO Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -292.0%
Net Margin -312.0%
ROE -1,744.3%
ROA -4.0%
FCF Margin 58.6%

GOCO vs Finance Sector: How GoHealth, Inc. Compares

How GoHealth, Inc. compares to Finance sector averages

Net Margin
GOCO -312.0%
vs
Sector Avg 25.0%
GOCO Sector
ROE
GOCO -1,744.3%
vs
Sector Avg 12.0%
GOCO Sector
Current Ratio
GOCO 2.0x
vs
Sector Avg 1.2x
GOCO Sector
Debt/Equity
GOCO 306.5x
vs
Sector Avg 2.0x
GOCO Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is GoHealth, Inc. Stock Overvalued? GOCO Valuation Analysis 2026

Based on fundamental analysis, GoHealth, Inc. shows some fundamental concerns relative to the Finance sector in 2026.

Return on Equity
-1,744.3%
Sector avg: 12%
Net Profit Margin
-312.0%
Sector avg: 25%
Revenue Growth
N/A
Year-over-year
Debt/Equity
306.49x
Sector avg: 2x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

GoHealth, Inc. Balance Sheet: GOCO Debt, Cash & Liquidity

Current Ratio
2.03x
Quick Ratio
2.03x
Debt/Equity
306.49x
Debt/Assets
0.0%
Interest Coverage
-1.94x
Long-term Debt
$653.1M

GOCO Revenue & Earnings Growth: 5-Year Financial Trend

GOCO 5-year financial data: Year 2021: Revenue $1.1B, Net Income -$57.1M, EPS $-0.22. Year 2022: Revenue $1.1B, Net Income -$44.3M, EPS $-3.35. Year 2023: Revenue $1.1B, Net Income -$189.4M, EPS $-26.80. Year 2024: Revenue $798.9M, Net Income -$148.7M, EPS $-17.72. Year 2025: Revenue $798.9M, Net Income -$63.3M, EPS $-7.19.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: GoHealth, Inc.'s revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-7.19 indicates the company is currently unprofitable.

GOCO Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
58.6%
Free cash flow / Revenue

GOCO Quarterly Earnings & Performance

Quarterly financial performance data for GoHealth, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $11.9M -$4.4M $-0.52
Q3 2025 $34.2M $6.8M $0.46
Q2 2025 $94.0M -$26.0M $-2.70
Q1 2025 $185.6M -$4.4M $-0.52
Q3 2024 $118.3M $6.8M $0.46
Q2 2024 $105.9M -$26.0M $-2.70
Q1 2024 $183.2M -$9.2M $-1.04
Q3 2023 $132.0M -$23.9M $-2.61

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

GoHealth, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$7.0M
Cash generated from operations
Dividends
None
No dividend program

GOCO SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for GoHealth, Inc. (CIK: 0001808220)

📋 Recent SEC Filings

Date Form Document Action
May 18, 2026 10-Q goco-20260331.htm View →
Apr 30, 2026 DEF 14A ny20066632x1_def14a.htm View →
Mar 31, 2026 10-K goco-20251231.htm View →
Mar 31, 2026 8-K goco-20260331.htm View →
Mar 20, 2026 8-K goco-20260318.htm View →

Frequently Asked Questions about GOCO

What is the AI rating for GOCO?

GoHealth, Inc. (GOCO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are GOCO's key strengths?

Claude: Positive operating cash flow of $7.0M demonstrates some business cash generation. Acceptable short-term liquidity with 2.03x current ratio. ChatGPT: Solid near-term liquidity (current and quick 2.02x). Meaningful revenue base (~$362M) if stabilized.

What are the risks of investing in GOCO?

Claude: Debt-to-equity ratio of 306.49x indicates technical insolvency and bankruptcy risk. 54.7% YoY revenue decline signals fundamental business model failure. ChatGPT: Extreme leverage (16.8x D/E) and negative interest coverage (-23x) indicate solvency risk. Severe revenue contraction (-54.7% YoY) with deeply negative margins.

What is GOCO's revenue and growth?

GoHealth, Inc. reported revenue of $11.9M.

Does GOCO pay dividends?

GoHealth, Inc. does not currently pay dividends.

Where can I find GOCO SEC filings?

Official SEC filings for GoHealth, Inc. (CIK: 0001808220) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is GOCO's EPS?

GoHealth, Inc. has a diluted EPS of $-2.36.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is GOCO a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, GoHealth, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is GOCO stock overvalued or undervalued?

Valuation metrics for GOCO: ROE of -1,744.3% (sector avg: 12%), net margin of -312.0% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.

Should I buy GOCO stock in 2026?

Our dual AI analysis gives GoHealth, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is GOCO's free cash flow?

GoHealth, Inc.'s operating cash flow is $7.0M, with capital expenditures of $0.0. FCF margin is 58.6%.

How does GOCO compare to other Finance stocks?

Vs Finance sector averages: Net margin -312.0% (avg: 25%), ROE -1,744.3% (avg: 12%), current ratio 2.03 (avg: 1.2).

Is GoHealth, Inc. carrying too much debt?

GOCO has a debt-to-equity ratio of 306.49x, which is above the Finance sector average of 2x. However, the current ratio of 2.03 suggests adequate short-term liquidity.

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Finance Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 19, 2026 | Data as of: 2026-03-31 | Powered by Claude AI